IP Library Granted Patent US 11,591,582
Granted Patent B2
US 11,591,582 · App. 16/340,257 · Granted Feb 28, 2023

TCRα homing endonuclease variants

Inventors: Jordan Jarjour (Seattle, WA); Mark Pogson (North Bend, WA)
Assignee: 2seventy bio, Inc.
C12N9/22C12N15/85
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,591,582
App. No.
16/340,257
Granted
Feb 28, 2023
Kind
B2
Abstract

The present disclosure provides improved genome editing compositions and methods for editing a TCRα gene.

Claims (17)

1. A polypeptide comprising an I-OnuI homing endonuclease (HE) variant that cleaves a target site in the human T cell receptor alpha (TCRα) gene, wherein the I-OnuI HE variant comprises an amino acid sequence that is at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 7 or SEQ ID NO: 8.

2. The polypeptide of claim 1 , wherein the I-OnuI HE variant comprises the amino acid sequence set forth in SEQ ID NO: 7 or SEQ ID NO: 8.

3. The polypeptide of claim 1 , wherein the polypeptide binds and cleaves said TCRα gene at the polynucleotide sequence set forth in SEQ ID NO: 17.

4. The polypeptide of claim 1 , further comprising a TALE DNA binding domain.

5. The polypeptide of claim 4 , wherein the TALE DNA binding domain comprises 11.5 TALE repeat units, and wherein the TALE DNA binding domain binds the polynucleotide sequence set forth in SEQ ID NO: 19.

6. The polypeptide of claim 4 , wherein the TALE DNA binding domain comprises 10.5 TALE repeat units, and wherein the TALE DNA binding domain binds the polynucleotide sequence set forth in SEQ ID NO: 18.

7. The polypeptide of claim 4 , wherein the polypeptide binds and cleaves said TCRα gene at the polynucleotide sequence set forth in SEQ ID NO: 20.

8. The polypeptide of claim 1 or claim 4 , further comprising:

(a) a peptide linker or a viral self-cleaving 2A peptide; and

(b) a 3′-5′ exonuclease.

9. The polypeptide of claim 8 , wherein the 3′-5′ exonuclease is Trex2.

10. A polypeptide, comprising an I-OnuI homing endonuclease (HE) variant that cleaves a target site in the human T cell receptor alpha (TCRα) gene and further comprising a TALE DNA binding domain, wherein the polypeptide comprises an amino acid sequence set forth in SEQ ID NO: 10 or an amino acid sequence that is at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 12.

11. The polypeptide of claim 4 , wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 10 or SEQ ID NO: 12.

12. A polynucleotide comprising a nucleotide sequence encoding a polypeptide comprising an I-OnuI homing endonuclease (HE) variant that cleaves a target site in the human T cell receptor alpha (TCRα) gene, wherein the I-OnuI HE variant comprises an amino acid sequence that is at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 7 or SEQ ID NO: 8.

13. A vector comprising the polynucleotide of claim 12 .

14. A cell comprising the polynucleotide of claim 12 .

15. The polynucleotide of claim 12 , wherein the nucleotide sequence encoding the polypeptide further comprises a nucleotide sequence encoding a TALE DNA binding domain.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2024
From: 2SEVENTY BIO, INC.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 067822/0847 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2021
From: BLUEBIRD BIO, INC.
To: 2SEVENTY BIO, INC.
Reel/Frame 057683/0099 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2019
From: JARJOUR, JORDAN; POGSON, MARK
To: BLUEBIRD BIO, INC.
Reel/Frame 049822/0637 →
Continuity (3)
Provisional Application 62414266 · Oct 28, 2016
Provisional Application 62406689 · Oct 11, 2016
Related Publication 20220186198A1 · Jun 16, 2022